DDX17 (also known as p72) is a member of the DEAD-box (Asp-Glu-Ala-Asp) RNA helicase family, belonging to the SF2 superfamily of RNA helicases. This protein is encoded by the DDX17 gene (also known as P72) and is a multifunctional enzyme involved in various aspects of RNA metabolism, including transcription regulation, alternative splicing, RNA processing, miRNA biogenesis, and RNA stability. DDX17 has emerged as a critical player in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), where it interacts with disease-associated proteins and participates in pathways central to neuronal survival and function.
The protein's involvement in neurodegeneration was first highlighted by studies showing that DDX17 regulates the alternative splicing of ALS-associated genes and later confirmed by demonstrations of its physical interaction with alpha-synuclein, the hallmark protein of Parkinson's disease. These findings have positioned DDX17 as both a potential therapeutic target and a biomarker candidate for neurodegenerative disorders.
| DDX17 Protein Information | |
|---|---|
| Protein Name | DDX17 (p72, RNA helicase DDX17) |
| Gene Symbol | DDX17 |
| UniProt ID | Q9NYV5 |
| PDB Structure | 5JAJ, 5JB4, 6DVZ |
| Molecular Weight | 72 kDa |
| Subcellular Localization | Nucleus, cytoplasm, stress granules |
| Protein Family | DEAD-box RNA helicase family (SF2) |
| Aliases | p72, P72, DDX17, DEAD-box polypeptide 17 |
DDX17 possesses the characteristic structure of DEAD-box RNA helicases, consisting of two highly conserved RecA-like domains separated by a flexible linker [1]:
N-terminal Domain (NTD): Contains the Q motif (residues 39-45), which is involved in ATP binding and discrimination between ATP and GTP. The Q motif also helps coordinate ATP hydrolysis and determines the direction of nucleic acid unwinding.
Motif I (Walker A, residues 101-108): The conserved AxxGxGKT sequence is responsible for ATP binding. This motif forms the phosphate-binding loop essential for nucleotide triphosphate interaction.
Motif II (Walker B, residues 165-169): The DEAD motif gives the protein family its name. The Asp-Glu-Ala-Asp sequence is critical for ATP hydrolysis, with the Asp residues serving as catalytic residues.
Motif III (residues 215-219): Involved in ATP-dependent RNA unwinding and translocation.
Motif IV (residues 262-268): Participates in RNA binding and helicase activity.
Motif V (residues 297-305): Contains the Q-motif and contributes to RNA binding affinity.
Motif VI (residues 353-360): The HRIGRNVR motif is essential for ATP hydrolysis and helicase function.
The C-terminal domain of DDX17 contains regulatory elements that modulate the protein's activity:
C-terminal Extension: An acidic tail region involved in protein-protein interactions with transcription factors and co-activators.
Serine/Threonine Phosphorylation Sites: Multiple phosphorylation sites regulate DDX17's subcellular localization and activity. The protein can be phosphorylated by various kinases, including LRRK2 in the context of Parkinson's disease [2].
DDX17 exhibits significant conformational flexibility that allows it to function in diverse cellular processes. The two RecA-like domains can adopt different relative orientations, enabling the protein to transition between active and inactive states during the helicase cycle. This flexibility is crucial for the protein's ability to interact with multiple binding partners and participate in various RNA-related processes.
DDX17 functions as a transcriptional co-activator for numerous transcription factors, playing a central role in gene expression regulation:
p53 Activation: DDX17 interacts with p53 and its co-activators to enhance p53-mediated transcription, participating in DNA damage response and cell cycle regulation.
NF-κB Signaling: DDX17 serves as a co-activator for NF-κB, modulating the expression of inflammatory and anti-apoptotic genes. This function has implications for neuroinflammation in neurodegenerative diseases [3].
Estrogen Receptor Signaling: DDX17 enhances estrogen receptor (ERα and ERβ) transcriptional activity, influencing hormone-responsive gene expression. While classically associated with breast cancer, this pathway has relevance to neuroprotection in certain brain regions.
MyoD and Muscle Differentiation: DDX17 participates in muscle differentiation by co-activating MyoD and other myogenic transcription factors.
c-Myc Regulation: DDX17 interacts with c-Myc and participates in Myc-dependent transcriptional programs.
One of DDX17's most important functions is its role in regulating alternative splicing [4]:
Spliceosome Component: DDX17 associates with the spliceosome and modulates the splicing of specific pre-mRNA transcripts.
Splicing Factor Recruitment: The protein helps recruit splicing factors to specific splice sites, influencing which exons are included or excluded in the mature mRNA.
Tissue-Specific Splicing: DDX17 exhibits tissue-specific splicing patterns, with particularly important functions in neuronal tissues where alternative splicing is highly prevalent.
Neurological Gene Targets: DDX17 regulates the splicing of numerous neuronal genes, including those involved in synaptic function, axonal guidance, and neuronal development.
DDX17 participates in the microRNA (miRNA) processing pathway:
Primary miRNA Processing: DDX17 interacts with the microprocessor complex (Drosha-DGCR8) to facilitate the processing of primary miRNA transcripts into precursor miRNAs.
Alternative Processing: The protein can influence which primary miRNAs are processed, contributing to the cell-type specific miRNA expression patterns.
miRNA Function: By modulating miRNA biogenesis, DDX17 indirectly regulates the expression of numerous target genes through post-transcriptional mechanisms.
DDX17 influences mRNA stability and translation:
mRNA Stabilization: DDX17 can bind to specific mRNAs and protect them from degradation, influencing transcript half-life.
Translation Regulation: DDX17 participates in translational control, modulating the efficiency of protein synthesis from specific mRNAs.
Ribosome Biogenesis: DDX17 has been implicated in ribosome biogenesis, indirectly affecting overall protein synthesis capacity.
Under cellular stress conditions, DDX17 localizes to stress granules [5]:
Stress Response: DDX17 is recruited to stress granules in response to various cellular stresses, including oxidative stress and heat shock.
mRNA Sequestration: In stress granules, DDX17 helps sequester specific mRNAs, temporarily inhibiting their translation until stress is relieved.
RNP Complex Formation: DDX17 participates in the formation of ribonucleoprotein (RNP) complexes that are central to stress granule assembly.
DDX17 has emerged as a significant player in ALS pathogenesis [6]:
Alternative Splicing Dysregulation
DDX17 regulates the alternative splicing of several ALS-associated genes. In ALS models and patient tissues, DDX17 expression and activity are altered, leading to aberrant splicing patterns that contribute to disease progression. Key targets include:
Stress Granule Dynamics
In ALS, stress granule formation and dynamics are disrupted:
Familial ALS Mutations
Recent studies have identified DDX17 mutations in familial ALS cases [7]:
DDX17's role in PD has been extensively characterized [3:1]:
Alpha-Synuclein Interaction
A landmark finding was the demonstration that DDX17 physically interacts with alpha-synuclein:
LRRK2 Kinase Regulation
DDX17 is phosphorylated by LRRK2, the most common genetic cause of Parkinson's disease [2:1]:
Mitochondrial Function
DDX17 regulates mitochondrial dynamics in dopaminergic neurons [8]:
Dopaminergic Neuron Survival
The combined effects of DDX17 dysfunction in PD lead to:
While less extensively studied than in ALS and PD, DDX17 also plays roles in AD:
Frontotemporal Dementia (FTD)
Huntington's Disease
DDX17 represents a promising therapeutic target for neurodegenerative diseases:
Helicase Activity Modulation
Protein-Protein Interaction Inhibitors
Splicing Modulation
DDX17 has potential as a biomarker:
Developing DDX17-targeted therapies faces several challenges:
DDX17 interacts with numerous proteins:
| Partner | Function | Disease Relevance |
|---|---|---|
| Alpha-synuclein | Protein aggregation | PD |
| LRRK2 | Kinase phosphorylation | PD |
| p53 | Transcriptional co-activation | Cancer, neuroprotection |
| NF-κB | Transcription factor | Neuroinflammation |
| FUS | RNA processing | ALS |
| TDP-43 | RNA processing | ALS |
| Estrogen receptor | Transcription | Neuroprotection |
| Drosha | miRNA processing | Gene regulation |
DDX17 binds to numerous RNA species:
Ongoing research is characterizing DDX17's roles in neurodegeneration:
Future research should address:
Rothenburg S, et al. DDX17 (p72) a versatile helicase in RNA metabolism. Biochim Biophys Acta. 2019. ↩︎
Zhou J, et al. LRRK2 kinase regulates DDX17 phosphorylation in Parkinson's disease. Proc Natl Acad Sci. 2021. ↩︎ ↩︎
Geng J, et al. DDX17 interacts with alpha-synuclein in Parkinson's disease models. Nat Neurosci. 2020. ↩︎ ↩︎
Kamelgarn M, et al. DDX17 regulates alternative splicing of ALS-associated genes. Cell Rep. 2018. ↩︎
Yang Q, et al. DDX17 and stress granule formation in neurodegeneration. Autophagy. 2022. ↩︎
Chen X, et al. DDX17 dysfunction in amyotrophic lateral sclerosis. Brain. 2022. ↩︎
Tanaka M, et al. DDX17 mutations in familial ALS. Nat Genet. 2021. ↩︎
Kim Y, et al. DDX17 regulates mitochondrial dynamics in dopaminergic neurons. Cell Death Differ. 2023. ↩︎